Reuters logo
BRIEF-Fate Therapeutics reports private financing
2016年11月22日 / 下午1点12分 / 1 年内

BRIEF-Fate Therapeutics reports private financing

Nov 22 (Reuters) - Fate Therapeutics Inc :

* Says entered into a definitive securities purchase agreement with certain institutional and other accredited investors

* Says private placement is being led by Redmile Group Llc with participation from BVF Partners L.p., Ecor1 Capital Llc and Franklin Advisers

* Says gross proceeds from private placement are expected to be about $57 million

* Fate Therapeutics - Redmile has agreed to purchase 2,819,549 shares of non-voting class a preferred stock at $13.30per share, each convertible into five shares of common stock

* Says remaining investors have agreed to purchase 7,236,837 shares of common stock at $2.66 per share

* Fate Therapeutics announces private financing Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below